Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) Shares Outstanding (Diluted Average) (2021 - 2025)

Cue Biopharma (CUE) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $94.7 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 68.18% to $94.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.7 million through Dec 2025, up 68.18% year-over-year, with the annual reading at $94.7 million for FY2025, 68.18% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $94.7 million in Q4 2025 for Cue Biopharma, down from $100.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $100.9 million in Q3 2025 to a low of $31.3 million in Q4 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $52.4 million across 5 years, with a median of $46.1 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): increased 8.49% in 2024 and later skyrocketed 100.56% in 2025.
  • Year by year, Shares Outstanding (Diluted Average) stood at $31.3 million in 2021, then increased by 13.95% to $35.6 million in 2022, then increased by 28.35% to $45.8 million in 2023, then increased by 23.11% to $56.3 million in 2024, then soared by 68.18% to $94.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CUE at $94.7 million in Q4 2025, $100.9 million in Q3 2025, and $84.9 million in Q2 2025.